Literature DB >> 31582359

Passive immunity for the treatment of influenza: quality not quantity.

Sanjat Kanjilal1, Michael J Mina2.   

Abstract

Mesh:

Substances:

Year:  2019        PMID: 31582359     DOI: 10.1016/S2213-2600(19)30265-6

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  5 in total

1.  Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.

Authors:  Niveditha Devasenapathy; Zhikang Ye; Mark Loeb; Fang Fang; Borna Tadayon Najafabadi; Yingqi Xiao; Rachel Couban; Philippe Bégin; Gordon Guyatt
Journal:  CMAJ       Date:  2020-05-22       Impact factor: 8.262

2.  Measles vaccine immune escape: Should we be concerned?

Authors:  Luojun Yang; Bryan T Grenfell; Michael J Mina
Journal:  Eur J Epidemiol       Date:  2019-11-01       Impact factor: 8.082

3. 

Authors:  Niveditha Devasenapathy; Zhikang Ye; Mark Loeb; Fang Fang; Borna Tadayon Najafabadi; Yingqi Xiao; Rachel Couban; Philippe Bégin; Gordon Guyatt
Journal:  CMAJ       Date:  2020-11-23       Impact factor: 8.262

Review 4.  Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.

Authors:  Tharmala Tharmalingam; Xiaobing Han; Ashley Wozniak; Laura Saward
Journal:  Hum Vaccin Immunother       Date:  2021-05-19       Impact factor: 4.526

5.  The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study.

Authors:  Mohammadreza Salehi; Mahdi Barkhori Mehni; Mohammadmehdi Akbarian; Samrand Fattah Ghazi; Nasim Khajavi Rad; Omid Moradi Moghaddam; SaeedReza Jamali Moghaddam; Masoumeh Hosseinzadeh Emam; Sayed Hamidreza Abtahi; Maryam Moradi; Fereshteh Ghiasvand
Journal:  Eur J Med Res       Date:  2022-02-03       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.